Prescription Medicines
Olodipine Tab. 5/40mg
- Product Category
- Complex hypertension treatment
- Active Ingredients
- Amlodipine besylate, olmesartan medoxomil
- Appearance
- Light yellow round film-coated tablet
- Reimbursement Code
- 648103500
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Amlodipine besylate (USP) ---------- 6.944mg (5mg as amlodipine)
Olmesartan medoxomil (EP) ---------- 40mg
- Additives: Silicified microcrystalline cellulose, Starcap 1500, magnesium stearate, Opadry II yellow (85F22093), pregelatinized starch, colloidal silicon oxide, croscarmellose sodium
2. Efficacy/Effectiveness
Treatment of essential hypertension in which blood pressure is not adequately controlled with amlodipine or olmesartan medoxomil monotherapy
3. Usage/Dosage
This medicine is administered 1 tablet once a day with water, regardless of meal. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (amlodipine or olmesartan medoxomil) before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient, you can consider switching to this medicine right away.
The maximum administered dose of this drug is 10/40 milligrams. Since the maximum blood pressure lowering effect occurs within 2 weeks after administration, the dose should be adjusted at intervals of 2 weeks or more, considering the patient's blood pressure response.
The recommended dosage is as follows.
- 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 5 mg of amlodipine or 20 mg of olmesartan medoxomil.
- 10/20 mg: Administer to patients whose blood pressure is not properly controlled with 20 mg of olmesartan medoxomil monotherapy.
- 5/40 mg: For patients whose blood pressure is not adequately controlled with the 5/20 mg strength.
- 10/40 mg: For patients whose blood pressure is not adequately controlled with the 5/40 mg strength.
∘ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, olmesartan medoxomil is used in patients with mild to moderate renal failure (creatine clearance 20-60mL/min).
The maximum dose is 20 mg once a day, and administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g. creatinine clearance < 20 mL/min) and patients on dialysis.
No. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure.
∘ Patients with decreased effective blood volume within blood vessels: Patients with the possibility of decreased effective blood volume within blood vessels (e.g., patients taking diuretics, especially patients with renal impairment)
It is recommended to start administration at a low dose while carefully observing the condition.
∘ Patients with hepatic impairment: Caution should be exercised when administering to patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily.
The maximum dosage is 20 milligrams once a day. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics.
This drug should not be administered to people with severe liver function impairment. (Refer to section 2. Do not administer to the following patients among the precautions for use)
∘ Elderly: Generally, administration is started at a low dose, and when adjusting the dose, the patient's renal or cardiac function, existing diseases, etc. should be taken into consideration.
Older people may need to monitor their blood pressure more closely and more frequently.
∘ Children: Safety and efficacy for pediatric patients under 18 years of age have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, it can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant women)
2. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant and lactating women
3) Patients with severe liver impairment
4) Patients with severe aortic stenosis
5) Patients with biliary obstruction
6) Kidney dialysis patients (no experience using it)
7) Shock patients
8) Patients with diabetes and/or moderate to severe renal impairment (glomerular filtration rate < 60mL/min/1.73m2) taking aliskiren preparations (see section 6. Drug interactions)
3. Administer with caution to the following patients.
1) Patients with low blood pressure who lack body fluids or salts (olmesartan medoxomil)
In patients with an activated renin-angiotensin system, such as patients with fluid or salt deficiency (e.g., those receiving high doses of diuretics), symptoms of hypotension may occur in the early stages of treatment with this drug.
Because this may occur, these patients should begin treatment while carefully observing their condition. If hypotension occurs, place the patient supine and instill saline solution if necessary.
Inject intravenously. Even if a temporary hypotensive reaction occurs, it does not indicate a contraindication to further treatment. Generally, once blood pressure is stabilized, there is no difficulty.
Treatment can continue.
2) Vasodilation
There have been rare reports of acute hypotension occurring after taking this drug due to gradual dilation of blood vessels due to amlodipine. Like other peripheral vasodilators, especially in severe
Caution should be exercised when administering this drug to patients with aortic stenosis.
3) Patients with severe obstructive coronary artery disease
In patients with severe obstructive coronary artery disease, the frequency, duration, or severity of angina or acute myocardial infarction may increase when treatment with calcium channel blockers is initiated or the dose is increased.
4) Congestive heart failure patients
In general, calcium channel blockers should be used with caution in patients with heart failure. NYHA Ⅲ with stabilized doses of angiotensin-converting enzyme (ACE) inhibitor, digoxin, and diuretic
As a result of a placebo-controlled clinical trial (minimum 6 months, average 14 months) with amlodipine (5-10 mg per day) on 1,153 patients with stage Ⅳ heart failure, survival or
There were no adverse effects on cardiac events (defined as life-threatening arrhythmias, acute myocardial infarction, or hospitalization for worsening heart failure). Patients with NYHA stage Ⅱ or Ⅲ heart failure
In an 8- to 12-week study of 697 patients, amlodipine was compared with placebo and there was no evidence of worsening heart failure as measured by exercise load, NYHA classification, signs, or left ventricular ejection fraction (LVEF).
There wasn't.
5) Patients with renal impairment
Because olmesartan medoxomil inhibits the renin-angiotensin-aldosterone system, changes in kidney function may occur in sensitive patients. Renal function is renin-angiotensin-
When ACE inhibitors or angiotensin receptor antagonists are administered to patients dependent on the activity of the aldosterone system (e.g., patients with severe congestive heart failure), oliguria or progressive symptoms may occur.
Acute azotemia and (rarely) acute renal failure and/or death may occur. Similar results may occur when administering this drug. Unilateral or bilateral
In a study in which ACE inhibitors were administered to patients with renal artery stenosis, increases in serum creatinine concentration and blood urea nitrogen (BUN) were reported. This drug can be used unilaterally or bilaterally
There have been no cases of long-term administration to patients with renal artery stenosis, but similar results are expected.
6) Patients with liver failure
Because amlodipine is extensively metabolized in the liver and has a plasma elimination half-life of 56 hours, caution should be exercised when administering this drug to patients with hepatic impairment. (Refer to the usage/dosage section)
4. Adverse reactions
1) Combination of olmesartan medoxomil and amlodipine
(1) Clinical trial results
The safety of this drug was evaluated in clinical trials involving 2,892 patients.
Adverse reactions were reported by body organ as follows. Frequency of occurrence is classified as follows; Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Occasionally (≥ 1/1,000, < 1/100); Rare (≥ 1/10,000, < 1/1,000); Very rare (< 1/10,000), unknown frequency (impossible to estimate from available data)
- Table - (Refer to manual)
(2) Domestic post-marketing survey results
① As a result of a post-marketing survey conducted on 1,172 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.61% (54/1,172 people, 66 cases) regardless of causal relationship.
Among these, the occurrence rate of serious adverse events was 0.43% (5/1,172 people, 5 cases), with dizziness, cholelithiasis, female breast neoplasms, worsening cerebral infarction, and gum bleeding reported at 0.09% (1 person, 1 case) each.
There were no serious adverse drug reactions for which a causal relationship with this drug could not be ruled out.
The incidence of unexpected adverse events was reported to be 1.88% (22/1,172 people, 27 cases) regardless of causal relationship, with postural dizziness at 0.26% (3 people, 3 cases), chest pain, and cold respectively.
0.17% (2 people, 2 cases), increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, general pain, hypoglycemia, weight loss, heartburn, gastroenteritis, cholelithiasis, shingles, double vision,
Female breast neoplasms, insomnia, worsening cerebral infarction, and gum bleeding were each found to be 0.09% (1 person, 1 case). Among these, unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out.
The incidence rate was 0.51% (6 people, 7 cases), positional dizziness was reported at 0.26% (3 people, 3 cases), and laryngitis, arthritis, systemic pain, and heartburn were reported at 0.09% (1 person, 1 case).
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, there were no statistically significantly more adverse events reported for this drug compared to the adverse events reported for all other drugs.
2) Olmesartan medoxomil
In placebo-controlled clinical trials, the adverse reaction that occurred in more than 1% of patients administered olmesartan medoxomil and occurred more frequently than placebo-treated patients was dizziness. Other adverse reactions that showed similar or higher occurrence in placebo-treated patients were back pain, bronchitis, increased creatine phosphatase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, It was sinusitis and cough.
Adverse reactions reported during post-marketing use are as follows.
◦ Systemic: Asthenia, angioedema
◦ Digestive system: Vomiting, chronic malabsorption (sprue)-like intestinal disease (see section 5. General precautions)
◦ Musculoskeletal system: Rhabdomyolysis
◦ Urogenital system: Acute renal failure, increased blood creatinine
◦ Skin and appendages: hair loss, itching, hives
◦ Hepatobiliary disorders: Autoimmune hepatitis*
*Autoimmune hepatitis with an incubation period of several months to several years has been reported overseas after marketing. These events were reversible after discontinuation of olmesartan treatment.
◦ Test value: hyperkalemia
clinical trial
Data from one controlled clinical trial and epidemiological study suggested that high doses of olmesartan may increase cardiovascular risk in patients with diabetes, but this was not conclusive. The randomized, placebo-controlled, double-blind ROADMAP (Randomized Olmesartan And Diabetes Microalbuminuria Prevention) study administered 40 mg of olmesartan medoxomil per day or placebo to 4,447 patients with type 2 diabetes, normoalbuminuria, and at least one additional cardiovascular risk factor.
In this clinical trial, olmesartan medoxomil met the main endpoint by delaying the onset of microalbuminuria, but was not effective in reducing glomerular filtration rate (GFR).
Deaths due to cardiovascular disease (sudden cardiac death, fatal myocardial infarction, fatal stroke, and reperfusion death) increased in the olmesartan medoxomil group compared to the placebo group. (15 in the olmesartan medoxomil group, 3 in the placebo group, HR=4.9, 95% Cl 1.4-17.0). However, the risk of non-fatal myocardial infarction was low in the olmesartan medoxomil group (HR=0.64, 95% Cl 0.35-1.18).
For additional safety information, refer to the olmesartan medoxomil single-substance labeling.
3) Amlodipine
In placebo-controlled clinical trials conducted on patients with hypertension and angina pectoris, the most common adverse reactions were as follows.
◦ Vascular system: flushing
◦ Whole body: fatigue, swelling
◦ Cardiovascular system: Heart palpitations
◦ Central and peripheral nervous system: dizziness, headache, drowsiness
◦ Digestive system: abdominal pain, nausea
No clinically significant laboratory abnormalities related to this drug were observed in clinical trials.
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization.
Leukopenia, thrombocytopenia, and toxic epidermal necrolysis have been reported (frequency unknown).
For additional safety information, refer to the amlodipine single-substance labeling.
5. General precautions
1) Discontinuation of beta blocker administration
Since amlodipine is not a beta blocker, there may be risks that occur if beta blocker administration is suddenly stopped. When beta-blocker administration is stopped, the amount of beta-blocker
It should decrease gradually.
2) Inhibition of renin-angiotensin-aldosterone
In patients whose vascular tone and renal function depend primarily on the renin–angiotensin–aldosterone system, such as those with severe congestive heart failure or renal disease including renal artery stenosis,
In some cases, coadministration with other drugs that affect this system has been associated with hypotension, azotemia, oliguria, or, in rare cases, acute renal failure.
3) Patients with renovascular hypertension
When angiotensin-converting enzyme (ACE) inhibitors are administered to patients with unilateral or bilateral renal artery stenosis, the risk of severe hypotension and renal dysfunction increases.
4) Hyperkalemia
As with other drugs that affect the renin-angiotensin system, hyperkalemia may occur when this drug is administered to patients with renal and/or heart failure.
Close monitoring of serum potassium is required when this medicine is used with drugs that may increase potassium levels.
5) Aortic and mitral stenosis, obstructive/hypertrophic myocardial disease
As with other vasodilators, special caution is required for patients with aortic or mitral stenosis or obstructive or hypertrophic cardiomyopathy.
6) Primary aldosteronism
In general, patients with primary aldosteronism are not responsive to antihypertensive drugs that inhibit the renin-angiotensin system, so administration of this drug to these patients is not recommended.
Not recommended.
7) Pregnancy
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, those planning to become pregnant
Patients should be switched to an alternative antihypertensive treatment with an established safety profile for use during pregnancy. If pregnancy is diagnosed, treatment with an angiotensin II receptor antagonist should, as soon as possible,
Treatment should be discontinued and, if appropriate, treatment with another treatment should be initiated.
8) Chronic malabsorption (Sprue)-like intestinal disease: An adverse event after overseas marketing was severe chronic diarrhea accompanied by significant weight loss in patients who had taken this drug for several months to several years.
The incident was reported. Villus retraction was commonly observed in the patient's intestinal biopsy. If the patient develops these symptoms during treatment and no other cause is identified, this medicine
Discontinuation of administration should be considered. If symptoms disappear and chronic malabsorption-like intestinal disease is confirmed on biopsy, this medicine should not be taken again.
9) Other
In patients with ischemic heart disease or ischemic cerebrovascular disease, excessive lowering of blood pressure may cause myocardial infarction or stroke.
6. Drug interactions
1) No significant pharmacokinetic interaction was observed when amlodipine and olmesartan medoxomil were used together. Studies have not been conducted on drug interactions between this drug and other medications.
2) Amlodipine
① In the case of amlodipine, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, long-acting nitrate agents,
It is safe when used in combination with nitroglycerin sublingual tablets, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic agents.
② Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
③ Grapefruit juice: When amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability.
Co-administration is not recommended.
④ Effects of other drugs on amlodipine:
- Cimetidine: When administered in combination with amlodipine, there was no effect on the pharmacokinetics of amlodipine.
- Aluminum/magnesium (antacid): When administered in combination with aluminum/magnesium antacid and a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
- Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine.
When amlodipine and sildenafil are administered together, each drug independently exerts its own blood pressure lowering effect.
- Cytochrome P3A4 inhibitor: When administered in combination with a cytochrome P3A4 inhibitor (erythromycin in young adults and diltiazem in elderly adults), the plasma concentration of amlodipine increases by 22%, respectively.
and increased by 50%, but no clinical correlation has been identified. Amlodipine's plasma
The possibility of increasing concentrations to levels higher than those seen in co-administration with diltiazem cannot be ruled out. Amlodipine is administered in combination with a cytochrome P3A4 inhibitor.
Administer with caution. However, no adverse reactions resulting from this drug interaction have been reported.
- CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentrations of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
⑤ Effects of amlodipine on other drugs:
- Atorvastatin: When multiple doses of 80 mg of atorvastatin and 10 mg of amlodipine were coadministered, there was no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
- Digoxin: When amlodipine and digoxin were co-administered to normal volunteers, there was no change in serum digoxin levels or renal clearance of digoxin.
- Ethanol (alcohol): There was no significant change in the pharmacokinetics of ethanol during single and repeated administration of 10 mg amlodipine.
- Warfarin: When amlodipine and warfarin were administered together, there was no effect on the warfarin-prothrombin reaction time.
- Cyclosporine: In a pharmacokinetic study on cyclosporine, amlodipine did not significantly change the pharmacokinetics of cyclosporine.
3) Olmesartan medoxomil
① Potassium supplements and potassium-sparing diuretics: When looking at the administration of other drugs that act on the renin-angiotensin system, potassium-sparing diuretics, potassium supplements, and preparations containing potassium salts
Alternatively, if this drug is co-administered with an agent that can increase serum potassium levels (heparin), serum potassium levels may increase.
② The blood pressure lowering effect of this drug may be increased when administered in combination with other antihypertensive drugs.
③ Lithium: There are reports that when angiotensin-converting enzyme (ACE) inhibitors and lithium are administered together, serum lithium levels reversibly increase and toxicity occurs. This phenomenon also occurs with this drug.
Because it has been reported very rarely, coadministration of this drug with lithium is not recommended.
④ Non-steroidal anti-inflammatory analgesics: When used in combination with other angiotensin II receptor antagonists and non-steroidal anti-inflammatory analgesics (e.g., aspirin over 3 g per day, COX-2 inhibitors), the decrease in glomerular filtration rate may increase. This risk is increased in patients with acute renal failure. Therefore, when starting treatment, it is recommended to replenish fluids and monitor renal function.
Recommended. Also, like other angiotensin II receptor antagonists, the antihypertensive effect of this drug may be weakened by nonsteroidal anti-inflammatory drugs.
⑤ Dual blockade of the renin-angiotensin system. Renin-angiotensin system caused by combined administration of angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), or aliskiren.
Dual blockade of the Renin-Angiotensin system is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared with monotherapy.
Therefore, for patients taking this drug concurrently with other drugs that act on the angiotensin system, the patient's condition, including blood pressure, renal function, and electrolyte concentration, should be closely monitored.
Do not administer this drug and aliskiren together in patients with diabetes and/or renal impairment (glomerular filtration rate <60mL/min/1.73m2).
⑥ Others: No serious drug interactions were reported when olmesartan medoxomil was administered in combination with digoxin or warfarin to healthy volunteers. Olmesartan medoxomil
Bioavailability did not change significantly when administered in combination with antacids [Al(OH)3/Mg(OH)2]. This drug is not metabolized by the cytochrome P450 system and is not metabolized by P450 enzymes.
It doesn't affect anything. Therefore, interactions with drugs that are inhibited, induced, or metabolized by this enzyme are not expected.
7. Administration to pregnant women
1) Olmesartan medoxomil: Drugs that act directly on the renin-angiotensin system can cause damage and death to the fetus and newborn when administered to a pregnant woman.
Dozens of cases have been reported in patients taking angiotensin-converting enzyme (ACE) inhibitors. If you are found to be pregnant, you should stop taking this medicine as soon as possible.
When drugs that act directly on the renin-angiotensin system are administered in the second and third trimesters of pregnancy, the risk includes hypotension, cranial immaturity in newborns, anuria, reversible or irreversible renal failure, and death.
It may cause damage to the fetus. Oligohydramnios, thought to be caused by decreased renal function in the fetus, has been reported. In this case, oligohydramnios causes fetal limb contractures and craniofacial
It is associated with aplasia and pulmonary hypoplasia. Although it is unclear whether this drug was caused by this drug, prematurity, intrauterine growth retardation, and patent ductus arteriosus have been reported. These adverse reactions occur during pregnancy
It does not seem to occur in cases of intrauterine drug exposure limited to the first stage. Even if the embryo or fetus is exposed to angiotensin II receptor inhibitors only during the first trimester, the pregnant woman may
That fact must be made known. Nevertheless, if the patient becomes pregnant, the doctor should have the patient stop using the drug as soon as possible.
In rare cases (less than 0.1%), there may be no alternative treatment to drugs that act on the renin-angiotensin system. In this case, the mother is exposed to potential harm to the fetus.
You must be aware of the risks and be aware of the condition of the amniotic fluid through repeated ultrasound examinations.
If oligohydramnios is observed, this medication should be discontinued unless absolutely necessary to maintain the mother's life. Uterine contraction test according to gestational age
stress testing (CST)) or nonstress testing (NST) or biophysical profiling (BPP) must be appropriately conducted.
Patients and physicians should be aware that oligohydramnios may not become apparent until after irreversible fetal injury has occurred. In infants exposed in utero to an angiotensin II receptor blocker,
Experienced infants should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be paid to supporting blood pressure and renal perfusion.
Do it. Blood transfusions or dialysis may be necessary as a means of reversing low blood pressure or replacing damaged kidney function.
2) When olmesartan medoxomil is administered orally to pregnant rats up to 1,000 mg/kg/day (240 times the maximum recommended human dose (MRHD) based on mg/m2) or to pregnant rabbits at 1 mg/kg/day (half of the maximum recommended human dose; a higher dose is lethal in rabbits.
No teratogenic effects were observed even when administered up to the point where the effect on fetal development could not be evaluated. However, when more than 1.6 mg/kg/day is administered to rats, the birth weight of the pups
and a significant decrease in weight gain was observed. In addition, when doses exceeding 8 mg/kg/day were administered, the time to reach embryological critical points was delayed (auricular differentiation, below).
A dose-dependent increase in the occurrence of renal pelvis relaxation (retardation of incisor eruption, abdominal hair growth, testicular descent, eyelid eruption, etc.) was observed. Developmental toxicity in rats
The dose at which no effects are observed is 0.3 mg/kg/day, which is approximately 1/10 of the maximum recommended human dose of 40 mg/day.
3) Amlodipine: There was no teratogenicity or other embryo/fetal toxicity when amlodipine maleate was orally administered up to 10 mg/kg/day (10 and 20 times the recommended human maximum dose of 10 mg amlodipine on a mg/m2 basis, respectively) to pregnant rats and rabbits during each major organogenesis. (Calculated based on a patient weighing 60 kg) However, for 14 days before mating and
In rats administered amlodipine maleate at a dose equivalent to 10 mg/kg/day during mating and pregnancy, fetal size was significantly reduced (approximately 50%) and intrauterine death occurred.
The number increased significantly (approximately 5-fold). When amlodipine maleate was administered to rats at the above dose, the pregnancy period and delivery period were delayed. Appropriate and well for pregnant women
There were no controlled clinical trials. During pregnancy, amlodipine should be used only when the potential benefits outweigh the potential risks to the fetus.
8. Administration to nursing mothers
It is not known whether olmesartan medoxomil passes into breast milk. However, in rats, olmesartan was released at low concentrations. Limited data in lactating mothers suggest that amlodipine passes into human breast milk. Because there is a possibility that adverse reactions may occur in infants, nursing mothers should stop breastfeeding or administer this drug, considering the importance of this drug.
9. Administration to children
Safety and efficacy have not been established for pediatric patients under the age of 18, so administration of this drug is not recommended.
10. Administration to elderly people
In clinical trials of this drug, 20% (384/1940) were over 65 years of age, and 3% (62/1940) were over 75 years of age, so there was no difference in safety and efficacy observed between elderly patients over 65 years of age and younger patients. However, it cannot be ruled out that a more sensitive reaction may occur in some elderly people.
When amlodipine was administered orally, the time to peak plasma concentration was similar in young and elderly patients. There was a tendency for amlodipine clearance to decrease in elderly patients, resulting in increased AUC and elimination half-life. The increase in AUC and elimination half-life in patients with congestive heart failure was expected given the age group of patients in this study.
In patients with hypertension, the AUC of olmesartan at steady state increased by approximately 35% in elderly patients (65 to 75 years old) compared to young patients, and increased by approximately 44% in patients aged 75 or older. This may be partly related to the average decrease in renal function in this patient group. In general, dose selection for the elderly should be cautious, usually starting at the lowest dose of the dosage range, and taking into account the frequent decline in liver, kidney, and heart function in the elderly, as well as concomitant diseases or concomitant medications.
11. Treatment in case of overdose
There are no reports of studies on overdose of this drug in humans.
1) Amlodipine
In mice and rats, a single oral dose of amlodipine maleate equivalent to 40 mg/kg of amlodipine and 100 mg/kg of amlodipine is a lethal dose. Amlodipine 4 mg/kg in dogs
As described above, single oral administration of amlodipine maleate (11 times or more than the recommended maximum human dose based on mg/m2) caused significant peripheral vasodilation and hypotension.
Overdosage may cause excessive peripheral vasodilation with marked hypotension, which may result in tachycardia.
In case of overdose of this drug, it is necessary to frequently monitor cardiac and respiratory function and frequently measure blood pressure. If hypotension occurs, cardiovascular support therapy, including raising blood pressure, and
Body fluid administration must be performed. If hypotension does not respond to these therapies, attention should be paid to circulating fluid volume and urine output, and administration of vasopressors such as phenylephrine may be recommended.
must be considered. Intravenous calcium gluconate may help reverse calcium channel blockage. Because amlodipine is highly bound to proteins, hemodialysis may not help.
There is a possibility.
Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Perfusion and cardiac output
Early resuscitative measures for maintenance (including fluid overload) may be a precipitating factor.
2) Olmesartan medoxomil
Overdose data in humans are limited. The most frequent symptoms of overdose are low blood pressure and tachycardia. When parasympathetic stimulation occurs, bradycardia occurs.
It can happen. If symptomatic hypotension occurs, supportive treatment should be initiated. It is not known whether this drug is removed by hemodialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Avoid humidity and heat, and store carefully to avoid direct exposure to light.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) Amlodipine
① Carcinogenicity
There was no evidence of carcinogenicity in rats and mice administered amlodipine 0.5, 1.25, or 2.5 mg/kg/day with food for 2 years. Additionally, the highest dose administered in this study was
It was close to the maximum tolerating dose of mice (in mice, the dose was close to the maximum recommended clinical dose of 10 mg/day on a mg/m2 basis,
In rats, 2.5 times the maximum recommended clinical dose, calculated based on a 60 kg patient)
② Mutability
In mutagenic tests, amlodipine maleate had no effect on gene or chromosome levels.
③ Fertility abnormalities
Rats treated with amlodipine at doses up to 10 mg/kg/day (10 times the maximum recommended clinical dose of 10 mg on a mg/m2 basis) for 64 days in males and 14 days in females prior to mating.
treatment) did not show any effect on fertility.
2) Olmesartan medoxomil
① Carcinogenicity
Olmesartan was not carcinogenic when administered orally to rats for up to 2 years. The maximum test dose of 2,000 mg/kg/day is the maximum recommended dose in humans on a mg/m2 basis.
It was 480 times the (MRHD) of 40 mg/day. 6-month dosing experiment in p53 knockout mice administered up to 1,000 mg/kg/day (about 120 times the MRHD) and Hras2 transformation
As a result of a 6-month administration test in mice, this drug was not found to be carcinogenic.
② Mutability
Olmesartan medoxomil and olmesartan were tested according to the results of an in vitro Syrian hamster embryo cell transformation assay.
It was negative, and there was no evidence of genotoxicity in the bacterial mutagenicity test (Ames test). However, both drugs were used in cells cultured in vitro (Chinese
Both drugs also tested positive for thymidine kinase mutations in an in vitro mouse lymphoma test.
When olmesartan medoxomil was orally administered up to 2,000 mg/kg, an in vivo mutation test was conducted in MutaMouse intestines and kidneys and an experiment was conducted to measure osteoclasticity in mouse bone marrow.
The result was negative. (Olmesartan was not tested.)
③ Fertility abnormalities
In a test where olmesartan was administered up to 1,000 mg/kg/day (240 times the MRHD) 9 weeks before mating in males and 2 weeks before mating in females, it did not affect the fertility of rats.
didn't
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Aluⅹ3)
7. Period of use
36 months from date of manufacture
- Active ingredient: Amlodipine besylate (USP) ---------- 6.944mg (5mg as amlodipine)
Olmesartan medoxomil (EP) ---------- 40mg
- Additives: Silicified microcrystalline cellulose, Starcap 1500, magnesium stearate, Opadry II yellow (85F22093), pregelatinized starch, colloidal silicon oxide, croscarmellose sodium
2. Efficacy/Effectiveness
Treatment of essential hypertension in which blood pressure is not adequately controlled with amlodipine or olmesartan medoxomil monotherapy
3. Usage/Dosage
This medicine is administered 1 tablet once a day with water, regardless of meal. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (amlodipine or olmesartan medoxomil) before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient, you can consider switching to this medicine right away.
The maximum administered dose of this drug is 10/40 milligrams. Since the maximum blood pressure lowering effect occurs within 2 weeks after administration, the dose should be adjusted at intervals of 2 weeks or more, considering the patient's blood pressure response.
The recommended dosage is as follows.
- 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 5 mg of amlodipine or 20 mg of olmesartan medoxomil.
- 10/20 mg: Administer to patients whose blood pressure is not properly controlled with 20 mg of olmesartan medoxomil monotherapy.
- 5/40 mg: For patients whose blood pressure is not adequately controlled with the 5/20 mg strength.
- 10/40 mg: For patients whose blood pressure is not adequately controlled with the 5/40 mg strength.
∘ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, olmesartan medoxomil is used in patients with mild to moderate renal failure (creatine clearance 20-60mL/min).
The maximum dose is 20 mg once a day, and administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g. creatinine clearance < 20 mL/min) and patients on dialysis.
No. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure.
∘ Patients with decreased effective blood volume within blood vessels: Patients with the possibility of decreased effective blood volume within blood vessels (e.g., patients taking diuretics, especially patients with renal impairment)
It is recommended to start administration at a low dose while carefully observing the condition.
∘ Patients with hepatic impairment: Caution should be exercised when administering to patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily.
The maximum dosage is 20 milligrams once a day. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics.
This drug should not be administered to people with severe liver function impairment. (Refer to section 2. Do not administer to the following patients among the precautions for use)
∘ Elderly: Generally, administration is started at a low dose, and when adjusting the dose, the patient's renal or cardiac function, existing diseases, etc. should be taken into consideration.
Older people may need to monitor their blood pressure more closely and more frequently.
∘ Children: Safety and efficacy for pediatric patients under 18 years of age have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, it can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant women)
2. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant and lactating women
3) Patients with severe liver impairment
4) Patients with severe aortic stenosis
5) Patients with biliary obstruction
6) Kidney dialysis patients (no experience using it)
7) Shock patients
8) Patients with diabetes and/or moderate to severe renal impairment (glomerular filtration rate < 60mL/min/1.73m2) taking aliskiren preparations (see section 6. Drug interactions)
3. Administer with caution to the following patients.
1) Patients with low blood pressure who lack body fluids or salts (olmesartan medoxomil)
In patients with an activated renin-angiotensin system, such as patients with fluid or salt deficiency (e.g., those receiving high doses of diuretics), symptoms of hypotension may occur in the early stages of treatment with this drug.
Because this may occur, these patients should begin treatment while carefully observing their condition. If hypotension occurs, place the patient supine and instill saline solution if necessary.
Inject intravenously. Even if a temporary hypotensive reaction occurs, it does not indicate a contraindication to further treatment. Generally, once blood pressure is stabilized, there is no difficulty.
Treatment can continue.
2) Vasodilation
There have been rare reports of acute hypotension occurring after taking this drug due to gradual dilation of blood vessels due to amlodipine. Like other peripheral vasodilators, especially in severe
Caution should be exercised when administering this drug to patients with aortic stenosis.
3) Patients with severe obstructive coronary artery disease
In patients with severe obstructive coronary artery disease, the frequency, duration, or severity of angina or acute myocardial infarction may increase when treatment with calcium channel blockers is initiated or the dose is increased.
4) Congestive heart failure patients
In general, calcium channel blockers should be used with caution in patients with heart failure. NYHA Ⅲ with stabilized doses of angiotensin-converting enzyme (ACE) inhibitor, digoxin, and diuretic
As a result of a placebo-controlled clinical trial (minimum 6 months, average 14 months) with amlodipine (5-10 mg per day) on 1,153 patients with stage Ⅳ heart failure, survival or
There were no adverse effects on cardiac events (defined as life-threatening arrhythmias, acute myocardial infarction, or hospitalization for worsening heart failure). Patients with NYHA stage Ⅱ or Ⅲ heart failure
In an 8- to 12-week study of 697 patients, amlodipine was compared with placebo and there was no evidence of worsening heart failure as measured by exercise load, NYHA classification, signs, or left ventricular ejection fraction (LVEF).
There wasn't.
5) Patients with renal impairment
Because olmesartan medoxomil inhibits the renin-angiotensin-aldosterone system, changes in kidney function may occur in sensitive patients. Renal function is renin-angiotensin-
When ACE inhibitors or angiotensin receptor antagonists are administered to patients dependent on the activity of the aldosterone system (e.g., patients with severe congestive heart failure), oliguria or progressive symptoms may occur.
Acute azotemia and (rarely) acute renal failure and/or death may occur. Similar results may occur when administering this drug. Unilateral or bilateral
In a study in which ACE inhibitors were administered to patients with renal artery stenosis, increases in serum creatinine concentration and blood urea nitrogen (BUN) were reported. This drug can be used unilaterally or bilaterally
There have been no cases of long-term administration to patients with renal artery stenosis, but similar results are expected.
6) Patients with liver failure
Because amlodipine is extensively metabolized in the liver and has a plasma elimination half-life of 56 hours, caution should be exercised when administering this drug to patients with hepatic impairment. (Refer to the usage/dosage section)
4. Adverse reactions
1) Combination of olmesartan medoxomil and amlodipine
(1) Clinical trial results
The safety of this drug was evaluated in clinical trials involving 2,892 patients.
Adverse reactions were reported by body organ as follows. Frequency of occurrence is classified as follows; Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Occasionally (≥ 1/1,000, < 1/100); Rare (≥ 1/10,000, < 1/1,000); Very rare (< 1/10,000), unknown frequency (impossible to estimate from available data)
- Table - (Refer to manual)
(2) Domestic post-marketing survey results
① As a result of a post-marketing survey conducted on 1,172 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.61% (54/1,172 people, 66 cases) regardless of causal relationship.
Among these, the occurrence rate of serious adverse events was 0.43% (5/1,172 people, 5 cases), with dizziness, cholelithiasis, female breast neoplasms, worsening cerebral infarction, and gum bleeding reported at 0.09% (1 person, 1 case) each.
There were no serious adverse drug reactions for which a causal relationship with this drug could not be ruled out.
The incidence of unexpected adverse events was reported to be 1.88% (22/1,172 people, 27 cases) regardless of causal relationship, with postural dizziness at 0.26% (3 people, 3 cases), chest pain, and cold respectively.
0.17% (2 people, 2 cases), increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, general pain, hypoglycemia, weight loss, heartburn, gastroenteritis, cholelithiasis, shingles, double vision,
Female breast neoplasms, insomnia, worsening cerebral infarction, and gum bleeding were each found to be 0.09% (1 person, 1 case). Among these, unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out.
The incidence rate was 0.51% (6 people, 7 cases), positional dizziness was reported at 0.26% (3 people, 3 cases), and laryngitis, arthritis, systemic pain, and heartburn were reported at 0.09% (1 person, 1 case).
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of the re-examination, there were no statistically significantly more adverse events reported for this drug compared to the adverse events reported for all other drugs.
2) Olmesartan medoxomil
In placebo-controlled clinical trials, the adverse reaction that occurred in more than 1% of patients administered olmesartan medoxomil and occurred more frequently than placebo-treated patients was dizziness. Other adverse reactions that showed similar or higher occurrence in placebo-treated patients were back pain, bronchitis, increased creatine phosphatase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, It was sinusitis and cough.
Adverse reactions reported during post-marketing use are as follows.
◦ Systemic: Asthenia, angioedema
◦ Digestive system: Vomiting, chronic malabsorption (sprue)-like intestinal disease (see section 5. General precautions)
◦ Musculoskeletal system: Rhabdomyolysis
◦ Urogenital system: Acute renal failure, increased blood creatinine
◦ Skin and appendages: hair loss, itching, hives
◦ Hepatobiliary disorders: Autoimmune hepatitis*
*Autoimmune hepatitis with an incubation period of several months to several years has been reported overseas after marketing. These events were reversible after discontinuation of olmesartan treatment.
◦ Test value: hyperkalemia
clinical trial
Data from one controlled clinical trial and epidemiological study suggested that high doses of olmesartan may increase cardiovascular risk in patients with diabetes, but this was not conclusive. The randomized, placebo-controlled, double-blind ROADMAP (Randomized Olmesartan And Diabetes Microalbuminuria Prevention) study administered 40 mg of olmesartan medoxomil per day or placebo to 4,447 patients with type 2 diabetes, normoalbuminuria, and at least one additional cardiovascular risk factor.
In this clinical trial, olmesartan medoxomil met the main endpoint by delaying the onset of microalbuminuria, but was not effective in reducing glomerular filtration rate (GFR).
Deaths due to cardiovascular disease (sudden cardiac death, fatal myocardial infarction, fatal stroke, and reperfusion death) increased in the olmesartan medoxomil group compared to the placebo group. (15 in the olmesartan medoxomil group, 3 in the placebo group, HR=4.9, 95% Cl 1.4-17.0). However, the risk of non-fatal myocardial infarction was low in the olmesartan medoxomil group (HR=0.64, 95% Cl 0.35-1.18).
For additional safety information, refer to the olmesartan medoxomil single-substance labeling.
3) Amlodipine
In placebo-controlled clinical trials conducted on patients with hypertension and angina pectoris, the most common adverse reactions were as follows.
◦ Vascular system: flushing
◦ Whole body: fatigue, swelling
◦ Cardiovascular system: Heart palpitations
◦ Central and peripheral nervous system: dizziness, headache, drowsiness
◦ Digestive system: abdominal pain, nausea
No clinically significant laboratory abnormalities related to this drug were observed in clinical trials.
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization.
Leukopenia, thrombocytopenia, and toxic epidermal necrolysis have been reported (frequency unknown).
For additional safety information, refer to the amlodipine single-substance labeling.
5. General precautions
1) Discontinuation of beta blocker administration
Since amlodipine is not a beta blocker, there may be risks that occur if beta blocker administration is suddenly stopped. When beta-blocker administration is stopped, the amount of beta-blocker
It should decrease gradually.
2) Inhibition of renin-angiotensin-aldosterone
In patients whose vascular tone and renal function depend primarily on the renin–angiotensin–aldosterone system, such as those with severe congestive heart failure or renal disease including renal artery stenosis,
In some cases, coadministration with other drugs that affect this system has been associated with hypotension, azotemia, oliguria, or, in rare cases, acute renal failure.
3) Patients with renovascular hypertension
When angiotensin-converting enzyme (ACE) inhibitors are administered to patients with unilateral or bilateral renal artery stenosis, the risk of severe hypotension and renal dysfunction increases.
4) Hyperkalemia
As with other drugs that affect the renin-angiotensin system, hyperkalemia may occur when this drug is administered to patients with renal and/or heart failure.
Close monitoring of serum potassium is required when this medicine is used with drugs that may increase potassium levels.
5) Aortic and mitral stenosis, obstructive/hypertrophic myocardial disease
As with other vasodilators, special caution is required for patients with aortic or mitral stenosis or obstructive or hypertrophic cardiomyopathy.
6) Primary aldosteronism
In general, patients with primary aldosteronism are not responsive to antihypertensive drugs that inhibit the renin-angiotensin system, so administration of this drug to these patients is not recommended.
Not recommended.
7) Pregnancy
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, those planning to become pregnant
Patients should be switched to an alternative antihypertensive treatment with an established safety profile for use during pregnancy. If pregnancy is diagnosed, treatment with an angiotensin II receptor antagonist should, as soon as possible,
Treatment should be discontinued and, if appropriate, treatment with another treatment should be initiated.
8) Chronic malabsorption (Sprue)-like intestinal disease: An adverse event after overseas marketing was severe chronic diarrhea accompanied by significant weight loss in patients who had taken this drug for several months to several years.
The incident was reported. Villus retraction was commonly observed in the patient's intestinal biopsy. If the patient develops these symptoms during treatment and no other cause is identified, this medicine
Discontinuation of administration should be considered. If symptoms disappear and chronic malabsorption-like intestinal disease is confirmed on biopsy, this medicine should not be taken again.
9) Other
In patients with ischemic heart disease or ischemic cerebrovascular disease, excessive lowering of blood pressure may cause myocardial infarction or stroke.
6. Drug interactions
1) No significant pharmacokinetic interaction was observed when amlodipine and olmesartan medoxomil were used together. Studies have not been conducted on drug interactions between this drug and other medications.
2) Amlodipine
① In the case of amlodipine, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, long-acting nitrate agents,
It is safe when used in combination with nitroglycerin sublingual tablets, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic agents.
② Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
③ Grapefruit juice: When amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability.
Co-administration is not recommended.
④ Effects of other drugs on amlodipine:
- Cimetidine: When administered in combination with amlodipine, there was no effect on the pharmacokinetics of amlodipine.
- Aluminum/magnesium (antacid): When administered in combination with aluminum/magnesium antacid and a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
- Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine.
When amlodipine and sildenafil are administered together, each drug independently exerts its own blood pressure lowering effect.
- Cytochrome P3A4 inhibitor: When administered in combination with a cytochrome P3A4 inhibitor (erythromycin in young adults and diltiazem in elderly adults), the plasma concentration of amlodipine increases by 22%, respectively.
and increased by 50%, but no clinical correlation has been identified. Amlodipine's plasma
The possibility of increasing concentrations to levels higher than those seen in co-administration with diltiazem cannot be ruled out. Amlodipine is administered in combination with a cytochrome P3A4 inhibitor.
Administer with caution. However, no adverse reactions resulting from this drug interaction have been reported.
- CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentrations of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
⑤ Effects of amlodipine on other drugs:
- Atorvastatin: When multiple doses of 80 mg of atorvastatin and 10 mg of amlodipine were coadministered, there was no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
- Digoxin: When amlodipine and digoxin were co-administered to normal volunteers, there was no change in serum digoxin levels or renal clearance of digoxin.
- Ethanol (alcohol): There was no significant change in the pharmacokinetics of ethanol during single and repeated administration of 10 mg amlodipine.
- Warfarin: When amlodipine and warfarin were administered together, there was no effect on the warfarin-prothrombin reaction time.
- Cyclosporine: In a pharmacokinetic study on cyclosporine, amlodipine did not significantly change the pharmacokinetics of cyclosporine.
3) Olmesartan medoxomil
① Potassium supplements and potassium-sparing diuretics: When looking at the administration of other drugs that act on the renin-angiotensin system, potassium-sparing diuretics, potassium supplements, and preparations containing potassium salts
Alternatively, if this drug is co-administered with an agent that can increase serum potassium levels (heparin), serum potassium levels may increase.
② The blood pressure lowering effect of this drug may be increased when administered in combination with other antihypertensive drugs.
③ Lithium: There are reports that when angiotensin-converting enzyme (ACE) inhibitors and lithium are administered together, serum lithium levels reversibly increase and toxicity occurs. This phenomenon also occurs with this drug.
Because it has been reported very rarely, coadministration of this drug with lithium is not recommended.
④ Non-steroidal anti-inflammatory analgesics: When used in combination with other angiotensin II receptor antagonists and non-steroidal anti-inflammatory analgesics (e.g., aspirin over 3 g per day, COX-2 inhibitors), the decrease in glomerular filtration rate may increase. This risk is increased in patients with acute renal failure. Therefore, when starting treatment, it is recommended to replenish fluids and monitor renal function.
Recommended. Also, like other angiotensin II receptor antagonists, the antihypertensive effect of this drug may be weakened by nonsteroidal anti-inflammatory drugs.
⑤ Dual blockade of the renin-angiotensin system. Renin-angiotensin system caused by combined administration of angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), or aliskiren.
Dual blockade of the Renin-Angiotensin system is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared with monotherapy.
Therefore, for patients taking this drug concurrently with other drugs that act on the angiotensin system, the patient's condition, including blood pressure, renal function, and electrolyte concentration, should be closely monitored.
Do not administer this drug and aliskiren together in patients with diabetes and/or renal impairment (glomerular filtration rate <60mL/min/1.73m2).
⑥ Others: No serious drug interactions were reported when olmesartan medoxomil was administered in combination with digoxin or warfarin to healthy volunteers. Olmesartan medoxomil
Bioavailability did not change significantly when administered in combination with antacids [Al(OH)3/Mg(OH)2]. This drug is not metabolized by the cytochrome P450 system and is not metabolized by P450 enzymes.
It doesn't affect anything. Therefore, interactions with drugs that are inhibited, induced, or metabolized by this enzyme are not expected.
7. Administration to pregnant women
1) Olmesartan medoxomil: Drugs that act directly on the renin-angiotensin system can cause damage and death to the fetus and newborn when administered to a pregnant woman.
Dozens of cases have been reported in patients taking angiotensin-converting enzyme (ACE) inhibitors. If you are found to be pregnant, you should stop taking this medicine as soon as possible.
When drugs that act directly on the renin-angiotensin system are administered in the second and third trimesters of pregnancy, the risk includes hypotension, cranial immaturity in newborns, anuria, reversible or irreversible renal failure, and death.
It may cause damage to the fetus. Oligohydramnios, thought to be caused by decreased renal function in the fetus, has been reported. In this case, oligohydramnios causes fetal limb contractures and craniofacial
It is associated with aplasia and pulmonary hypoplasia. Although it is unclear whether this drug was caused by this drug, prematurity, intrauterine growth retardation, and patent ductus arteriosus have been reported. These adverse reactions occur during pregnancy
It does not seem to occur in cases of intrauterine drug exposure limited to the first stage. Even if the embryo or fetus is exposed to angiotensin II receptor inhibitors only during the first trimester, the pregnant woman may
That fact must be made known. Nevertheless, if the patient becomes pregnant, the doctor should have the patient stop using the drug as soon as possible.
In rare cases (less than 0.1%), there may be no alternative treatment to drugs that act on the renin-angiotensin system. In this case, the mother is exposed to potential harm to the fetus.
You must be aware of the risks and be aware of the condition of the amniotic fluid through repeated ultrasound examinations.
If oligohydramnios is observed, this medication should be discontinued unless absolutely necessary to maintain the mother's life. Uterine contraction test according to gestational age
stress testing (CST)) or nonstress testing (NST) or biophysical profiling (BPP) must be appropriately conducted.
Patients and physicians should be aware that oligohydramnios may not become apparent until after irreversible fetal injury has occurred. In infants exposed in utero to an angiotensin II receptor blocker,
Experienced infants should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be paid to supporting blood pressure and renal perfusion.
Do it. Blood transfusions or dialysis may be necessary as a means of reversing low blood pressure or replacing damaged kidney function.
2) When olmesartan medoxomil is administered orally to pregnant rats up to 1,000 mg/kg/day (240 times the maximum recommended human dose (MRHD) based on mg/m2) or to pregnant rabbits at 1 mg/kg/day (half of the maximum recommended human dose; a higher dose is lethal in rabbits.
No teratogenic effects were observed even when administered up to the point where the effect on fetal development could not be evaluated. However, when more than 1.6 mg/kg/day is administered to rats, the birth weight of the pups
and a significant decrease in weight gain was observed. In addition, when doses exceeding 8 mg/kg/day were administered, the time to reach embryological critical points was delayed (auricular differentiation, below).
A dose-dependent increase in the occurrence of renal pelvis relaxation (retardation of incisor eruption, abdominal hair growth, testicular descent, eyelid eruption, etc.) was observed. Developmental toxicity in rats
The dose at which no effects are observed is 0.3 mg/kg/day, which is approximately 1/10 of the maximum recommended human dose of 40 mg/day.
3) Amlodipine: There was no teratogenicity or other embryo/fetal toxicity when amlodipine maleate was orally administered up to 10 mg/kg/day (10 and 20 times the recommended human maximum dose of 10 mg amlodipine on a mg/m2 basis, respectively) to pregnant rats and rabbits during each major organogenesis. (Calculated based on a patient weighing 60 kg) However, for 14 days before mating and
In rats administered amlodipine maleate at a dose equivalent to 10 mg/kg/day during mating and pregnancy, fetal size was significantly reduced (approximately 50%) and intrauterine death occurred.
The number increased significantly (approximately 5-fold). When amlodipine maleate was administered to rats at the above dose, the pregnancy period and delivery period were delayed. Appropriate and well for pregnant women
There were no controlled clinical trials. During pregnancy, amlodipine should be used only when the potential benefits outweigh the potential risks to the fetus.
8. Administration to nursing mothers
It is not known whether olmesartan medoxomil passes into breast milk. However, in rats, olmesartan was released at low concentrations. Limited data in lactating mothers suggest that amlodipine passes into human breast milk. Because there is a possibility that adverse reactions may occur in infants, nursing mothers should stop breastfeeding or administer this drug, considering the importance of this drug.
9. Administration to children
Safety and efficacy have not been established for pediatric patients under the age of 18, so administration of this drug is not recommended.
10. Administration to elderly people
In clinical trials of this drug, 20% (384/1940) were over 65 years of age, and 3% (62/1940) were over 75 years of age, so there was no difference in safety and efficacy observed between elderly patients over 65 years of age and younger patients. However, it cannot be ruled out that a more sensitive reaction may occur in some elderly people.
When amlodipine was administered orally, the time to peak plasma concentration was similar in young and elderly patients. There was a tendency for amlodipine clearance to decrease in elderly patients, resulting in increased AUC and elimination half-life. The increase in AUC and elimination half-life in patients with congestive heart failure was expected given the age group of patients in this study.
In patients with hypertension, the AUC of olmesartan at steady state increased by approximately 35% in elderly patients (65 to 75 years old) compared to young patients, and increased by approximately 44% in patients aged 75 or older. This may be partly related to the average decrease in renal function in this patient group. In general, dose selection for the elderly should be cautious, usually starting at the lowest dose of the dosage range, and taking into account the frequent decline in liver, kidney, and heart function in the elderly, as well as concomitant diseases or concomitant medications.
11. Treatment in case of overdose
There are no reports of studies on overdose of this drug in humans.
1) Amlodipine
In mice and rats, a single oral dose of amlodipine maleate equivalent to 40 mg/kg of amlodipine and 100 mg/kg of amlodipine is a lethal dose. Amlodipine 4 mg/kg in dogs
As described above, single oral administration of amlodipine maleate (11 times or more than the recommended maximum human dose based on mg/m2) caused significant peripheral vasodilation and hypotension.
Overdosage may cause excessive peripheral vasodilation with marked hypotension, which may result in tachycardia.
In case of overdose of this drug, it is necessary to frequently monitor cardiac and respiratory function and frequently measure blood pressure. If hypotension occurs, cardiovascular support therapy, including raising blood pressure, and
Body fluid administration must be performed. If hypotension does not respond to these therapies, attention should be paid to circulating fluid volume and urine output, and administration of vasopressors such as phenylephrine may be recommended.
must be considered. Intravenous calcium gluconate may help reverse calcium channel blockage. Because amlodipine is highly bound to proteins, hemodialysis may not help.
There is a possibility.
Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Perfusion and cardiac output
Early resuscitative measures for maintenance (including fluid overload) may be a precipitating factor.
2) Olmesartan medoxomil
Overdose data in humans are limited. The most frequent symptoms of overdose are low blood pressure and tachycardia. When parasympathetic stimulation occurs, bradycardia occurs.
It can happen. If symptomatic hypotension occurs, supportive treatment should be initiated. It is not known whether this drug is removed by hemodialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Avoid humidity and heat, and store carefully to avoid direct exposure to light.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) Amlodipine
① Carcinogenicity
There was no evidence of carcinogenicity in rats and mice administered amlodipine 0.5, 1.25, or 2.5 mg/kg/day with food for 2 years. Additionally, the highest dose administered in this study was
It was close to the maximum tolerating dose of mice (in mice, the dose was close to the maximum recommended clinical dose of 10 mg/day on a mg/m2 basis,
In rats, 2.5 times the maximum recommended clinical dose, calculated based on a 60 kg patient)
② Mutability
In mutagenic tests, amlodipine maleate had no effect on gene or chromosome levels.
③ Fertility abnormalities
Rats treated with amlodipine at doses up to 10 mg/kg/day (10 times the maximum recommended clinical dose of 10 mg on a mg/m2 basis) for 64 days in males and 14 days in females prior to mating.
treatment) did not show any effect on fertility.
2) Olmesartan medoxomil
① Carcinogenicity
Olmesartan was not carcinogenic when administered orally to rats for up to 2 years. The maximum test dose of 2,000 mg/kg/day is the maximum recommended dose in humans on a mg/m2 basis.
It was 480 times the (MRHD) of 40 mg/day. 6-month dosing experiment in p53 knockout mice administered up to 1,000 mg/kg/day (about 120 times the MRHD) and Hras2 transformation
As a result of a 6-month administration test in mice, this drug was not found to be carcinogenic.
② Mutability
Olmesartan medoxomil and olmesartan were tested according to the results of an in vitro Syrian hamster embryo cell transformation assay.
It was negative, and there was no evidence of genotoxicity in the bacterial mutagenicity test (Ames test). However, both drugs were used in cells cultured in vitro (Chinese
Both drugs also tested positive for thymidine kinase mutations in an in vitro mouse lymphoma test.
When olmesartan medoxomil was orally administered up to 2,000 mg/kg, an in vivo mutation test was conducted in MutaMouse intestines and kidneys and an experiment was conducted to measure osteoclasticity in mouse bone marrow.
The result was negative. (Olmesartan was not tested.)
③ Fertility abnormalities
In a test where olmesartan was administered up to 1,000 mg/kg/day (240 times the MRHD) 9 weeks before mating in males and 2 weeks before mating in females, it did not affect the fertility of rats.
didn't
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Aluⅹ3)
7. Period of use
36 months from date of manufacture
Product Updates
Total 10items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 10 | Olodipine Tab. 5/40mg | Precautions for use | 2026.02.12 | PDF0113_201404739_Precautions for use_Olodipine tablets 5/40mg.pdf |
| 9 | Olodipine Tab. 5/40mg | Precautions for use | 2026.02.12 | PDF0211_201404739_Precautions for use_Olodipine tablets 5/40mg.pdf |
| 8 | Olodipine Tab. 5/40mg | Precautions for use | 2024.08.30 | Olodipine Tablet 5│40mg_Precautions for Use Change Proposal and Change Table.pdfFile under review |
| 7 | Olodipine Tab. 5/40mg | Precautions for use | 2022.11.16 | Olodipine Tablet Change Proposal + Change Comparison Table.pdfFile under review |
| 6 | Olodipine Tab. 5/40mg | Precautions for use | 2022.03.16 | Change plan + change comparison table_Olodipine Tablet.pdfFile under review |
| 5 | Olodipine Tab. 5/40mg | Precautions for use | 2018.09.14 | PDF0720_201404739_Precautions for use (Olodipine tablets 5_40mg).pdf |
| 4 | Olodipine Tab. 5/40mg | Olodipine Tablet 5/40mg (Precautions for use... | 2016.07.08 | HWP40_Olodipine tablet 5,40 mg.hwp |
| 3 | Olodipine Tab. 5/40mg | Olodipine tablet 5/40 mg (precautions for use... | 2016.04.20 | HWP37_Olodipine tablet 5,40 mg.hwp |
| 2 | Olodipine Tab. 5/40mg | Olodipine tablet 5/40 mg (dosage, usage instructions... | 2015.09.10 | HWPOlmesartan medoxomil amlodipine besylate complex tablet container |
| 1 | Olodipine Tab. 5/40mg | Olodipine Tablet 5/40mg (Precautions for use... | 2015.07.15 | HWPPermit_Change Instruction_and_Change Comparison Table Olmesartan Medoxomil, |